Insmed Inc (INSM)
68.15
-0.17
(-0.25%)
USD |
NASDAQ |
Nov 04, 16:00
68.45
+0.30
(+0.44%)
After-Hours: 20:00
Insmed Enterprise Value: 11.68B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 11.68B |
| November 01, 2024 | 11.71B |
| October 31, 2024 | 11.52B |
| October 30, 2024 | 12.06B |
| October 29, 2024 | 12.18B |
| October 28, 2024 | 12.36B |
| October 25, 2024 | 12.18B |
| October 24, 2024 | 12.31B |
| October 23, 2024 | 12.35B |
| October 22, 2024 | 12.66B |
| October 21, 2024 | 12.41B |
| October 18, 2024 | 12.82B |
| October 17, 2024 | 12.77B |
| October 16, 2024 | 13.20B |
| October 15, 2024 | 12.84B |
| October 14, 2024 | 12.91B |
| October 11, 2024 | 12.82B |
| October 10, 2024 | 12.31B |
| October 09, 2024 | 12.00B |
| October 08, 2024 | 12.25B |
| October 07, 2024 | 12.10B |
| October 04, 2024 | 12.41B |
| October 03, 2024 | 12.26B |
| October 02, 2024 | 12.55B |
| October 01, 2024 | 12.52B |
| Date | Value |
|---|---|
| September 30, 2024 | 12.54B |
| September 27, 2024 | 12.38B |
| September 26, 2024 | 12.45B |
| September 25, 2024 | 12.42B |
| September 24, 2024 | 12.41B |
| September 23, 2024 | 12.27B |
| September 20, 2024 | 12.68B |
| September 19, 2024 | 12.81B |
| September 18, 2024 | 12.45B |
| September 17, 2024 | 12.51B |
| September 16, 2024 | 12.51B |
| September 13, 2024 | 12.75B |
| September 12, 2024 | 12.63B |
| September 11, 2024 | 12.43B |
| September 10, 2024 | 12.22B |
| September 09, 2024 | 12.27B |
| September 06, 2024 | 12.13B |
| September 05, 2024 | 12.45B |
| September 04, 2024 | 12.86B |
| September 03, 2024 | 12.52B |
| August 30, 2024 | 13.07B |
| August 29, 2024 | 13.04B |
| August 28, 2024 | 13.08B |
| August 27, 2024 | 13.18B |
| August 26, 2024 | 12.85B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.073B
Minimum
Mar 23 2020
13.50B
Maximum
Aug 22 2024
3.848B
Average
2.969B
Median
Oct 03 2022
Enterprise Value Benchmarks
| Fulcrum Therapeutics Inc | -70.35M |
| Alnylam Pharmaceuticals Inc | 33.06B |
| Eli Lilly and Co | 792.96B |
| Bioventus Inc | 1.282B |
| Entrada Therapeutics Inc | 190.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -220.52M |
| Revenue (Quarterly) | 93.42M |
| Total Expenses (Quarterly) | 292.17M |
| EPS Diluted (Quarterly) | -1.27 |
| Gross Profit Margin (Quarterly) | 77.34% |
| Profit Margin (Quarterly) | -236.0% |
| Earnings Yield | -8.14% |
| Normalized Earnings Yield | -7.585 |